Analytical Data
-
基因名
ARHGEF25
- Application
-
别名
ARHGEF25; ARHGP_HUMAN; GEFT ; Guanine nucleotide exchange factor GEFT
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q86VW2
-
表达区间
1-580aa
-
氨基酸序列
MRGGHKGGRC ACPRVIRKVL AKCGCCFARG GRESYSIAGS EGSISASAAS GLAAPSGPSS GLSSGPCSPG PPGPVSGLRR WLDHSKHCLS VETEADSGQA GPYENWMLEP ALATGEELPE LTLLTTLLEG PGDKTQPPEE ETLSQAPESE EEQKKKALER SMYVLSELVE TEKMYVDDLG QIVEGYMATM AAQGVPESLR GRDRIVFGNI QQIYEWHRDY FLQELQRCLK DPDWLAQLFI KHERRLHMYV VYCQNKPKSE HVVSEFGDSY FEELRQQLGH RLQLNDLLIK PVQRIMKYQL LLKDFLKYYN RAGMDTADLE QAVEVMCFVP KRCNDMMTLG RLRGFEGKLT AQGKLLGQDT FWVTEPEAGG LLSSRGRERR VFLFEQIIIF SEALGGGVRG GTQPGYVYKN SIKVSCLGLE GNLQGDPCRF ALTSRGPEGG IQRYVLQAAD PAISQAWIKH VAQILESQRD FLNALQSPIE YQRRESQTNS LGRPRGPGVG SPGRIQLGDQ AQGSTHTPIN GSLPSLLLSP KGEVARALLP LDKQALGDIP QAPHDSPPVS PTPKTPPCQA RLAKLDEDEL
-
分子量
63 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ARHGEF25, a member of the Rho guanine nucleotide exchange factor (GEF) family, has garnered significant attention in recent years due to its pivotal role in regulating Rho GTPases, which are essential for various cellular processes including cytoskeletal organization, cell migration, and proliferation. Research has indicated that ARHGEF25 may be implicated in several pathological conditions, including cancer metastasis and cardiovascular diseases, as its modulation can influence cell behavior and signaling pathways. Studies have shown that ARHGEF25 can interact with various signaling molecules, thus affecting the actin cytoskeleton and contributing to the dynamic changes in cell shape and movement. Given its potential as a therapeutic target, the development and characterization of recombinant ARHGEF25 protein are crucial for elucidating its function and role in disease. By producing ARHGEF25 as a recombinant protein, researchers can conduct detailed biochemical and structural analyses, enhancing our understanding of its mechanisms of action and interactions with other cellular components. Furthermore, this research could facilitate the identification of novel drug targets and treatment strategies for diseases where ARHGEF25 is dysregulated. Overall, the study of recombinant ARHGEF25 protein offers promising insights into its biological significance and potential therapeutic applications, emphasizing the need for further exploration in the context of cell signaling and disease modulation.
